Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01851642 · ClinicalTrials.gov registry record
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
A clinical trial of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF), sponsored by University of Florida.
- Recruiting
- Registry status
- 220
- Enrollment target
- 1
- Study location
NCT01851642: Recruiting study of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF), sponsored by University of Florida.
NCT01851642 is a study of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF) that is actively recruiting participants, run by University of Florida. The registered enrollment target is 220 participants, below the 2,333-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01851642, a study of Alpha-1 Antitrypsin Deficiency and Cystic Fibrosis (CF), is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
Primary Outcome
From every study participant, we will collect blood from a vein through the placement of an intravenous catheter (IV). We will complete various experiments that will allow us to see how well each participant's macrophage cells are working.
Conditions Studied
Interventions
- PROCEDURE History and physical exam.
- PROCEDURE Blood draw.
- PROCEDURE Pulmonary function testing.
- DRUG Albuterol inhaler.
Study Locations (1)
Florida
- Shands at the University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2007-08-09 |
| Est. Completion | 2033-07-20 |
What NCT01851642 shows while recruiting
NCT01851642 is an observational study that tracks outcomes without assigning an intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 2,333-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 4 interventions - of which History and physical exam. is the first listed.
NCT01851642 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01851642 about?
NCT01851642 is a clinical study titled "Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs". The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
What is the current status of trial NCT01851642?
This trial is currently recruiting. The enrollment target is 220 participants. The study started on 2007-08-09. Estimated completion is 2033-07-20.
What conditions does trial NCT01851642 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis (CF), AAT Deficiency, AATD.
What interventions are being tested in trial NCT01851642?
The interventions under investigation include: History and physical exam. (PROCEDURE), Blood draw. (PROCEDURE), Pulmonary function testing. (PROCEDURE), Albuterol inhaler. (DRUG).
Who is sponsoring clinical trial NCT01851642?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01851642 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01851642's enrollment target sits among peer trials
220 5th of 24 higher than 20 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
PiMZ Longitudinal Cohort (PiMZ Logic)
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
- NCT04421820 · 220 participants · Phase 1
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI